title: Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy.
abstract: OBJECTIVE
  To evaluate changes in Hepatitis C Virus (HCV) RNA both in plasma and Peripheral Blood Mononuclear Cells (PBMC) in onco-haematological patients.
  
  
  METHODS
  8 consecutive anti-HCV/HCV RNA-positive patients with onco-haematological diseases (5 with B-cell Non-Hodgkin Lymphoma and 3 with chronic lymphocytic leukaemia) were observed during chemotherapy and after its discontinuation. All were naïve to chemotherapy. HCV RNA was sought by Real Time Polymerase Chain Reaction in Light Cycler 1.5 in plasma and PBMC samples collected before, during and after chemotherapy.
  
  
  RESULTS
  An increase in HCV RNA of at least 1.5 log IU/mL in plasma and 1.1 log IU/ml in PBMC was observed in all 7 patients undergoing Rituximab-based chemotherapy; these patients showed a hepatic flare after discontinuation, life-threatening in one with cirrhosis. Also the 8th patient had cirrhosis, but was treated with Rituximab-sparing chemotherapy and did not show any increase in HCV RNA or a hepatic flare.
  
  
  CONCLUSIONS
  Rituximab-based chemotherapy favours an increase in HCV RNA in onco-haematological patients; this is followed by a hepatic flare, possibly immune-mediated and life threatening in cirrhotic patients.
authors: Department of Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy.
authors: Nicola
authors: N
authors: Coppola
authors: Mariantonietta
authors: M
authors: Pisaturo
authors: Salvatore
authors: S
authors: Guastafierro
authors: Gilda
authors: G
authors: Tonziello
authors: Antonello
authors: A
authors: Sica
authors: Valentina
authors: V
authors: Iodice
authors: Caterina
authors: C
authors: Sagnelli
authors: Maria Giovanna
authors: MG
authors: Ferrara
authors: Evangelista
authors: E
authors: Sagnelli
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification* / Q000502:physiology; D006526:Hepatitis C / Q000150:complications / Q000821:virology*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy / Q000821:virology*; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy / Q000821:virology*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D060888:Real-Time Polymerase Chain Reaction; D000069283:Rituximab; D019562:Viral Load; D014779:Virus Replication
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D012367:RNA, Viral; D000069283:Rituximab